EN | UA
EN | UA

Help Support

Back

High-dose dual vs bismuth quadruple therapy in H. pylori-infected individuals

H. pylori H. pylori
H. pylori H. pylori

To compare the effectiveness, safety, and compliance of two renowned therapies i.e. high-dose dual therapy and bismuth-based quadruple therapy for initial H. pylori eradication in Hainan Island, China.

See All

Key take away

High-dose dual therapy shows equivalent H. pylori eradication rates to bismuth-based quadruple therapy, with no significant difference in adverse effects, while exhibiting superior patient compliance.

Background

To compare the effectiveness, safety, and compliance of two renowned therapies i.e. high-dose dual therapy and bismuth-based quadruple therapy for initial H. pylori eradication in Hainan Island, China.

Method

A total of 846 people suffering from H. pylori illness were randomized into two groups:

  • Bismuth-containing quadruple therapy group: Esomeprazole 20 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg twice daily, plus colloidal Bismuth Pectin suspension 150 mg three times a day for 2 weeks
  • High-dose dual therapy group: Esomeprazole 20 mg four times a day + Amoxicillin 1000 mg three times a day for 2 weeks

A 13C urea breath test was conducted 4 weeks following the cessation of the therapy in order to evaluate the eradication rate. Adverse effects and compliance were assessed during the follow-up visits.

Result

The study results are summarized in the following Table 1:

There was no significant difference in the occurrence of adverse effects between the two groups (P = 0.129) - only 13.5% of patients in the dual therapy group (55 out of 407 patients) experienced adverse effects, while in the quadruple therapy group, it was 17.4% (70 out of 403 patients).

About 92.4% of patients (376 out of 407) stuck to their treatment regimen, presenting great compliance. In contrast, the quadruple therapy group had a slightly lower compliance rate of 86.6% (349 out of 403), which was significantly different (P = 0.007).

Conclusion

High-dose dual therapy demonstrated comparable eradication rates to bismuth-based quadruple therapy, with no significant differences in adverse effects. Nonetheless, the dual therapy group displayed higher adherence rates.

Source:

Clinics and Research in Hepatology and Gastroenterology

Article:

Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial

Authors:

Dan-Ni Liu et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: